Publications

Top

  1. Sok V, Marzan F, Roh M, Guo K, Legac J, Mwebaza N, Dorsey G, Rosenthal PJ, Aweeka FT, Huang L. Determination of sulfadoxine and pyrimethamine in microvolume human plasma using ultra high performance liquid chromatography-tandam mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Feb 15;1234:124030. doi: 10.1016/j.jchromb.2024.124030. Epub 2024 Jan 24. PMID: 38309043.

  2. The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms. J Med Virol. 2023 Nov; 95(11):e29216. Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Bodansky A, Kung A, Hoh R, Williams MC, Kerbleski M, Maison DP, Deveau TM, Munter SE, Lombardo J, Wrin T, Petropoulos CJ, Durstenfeld MS, Hsue PY, Kelly JD, Greenhouse B, Martin JN, Deeks SG, Peluso MJ, Henrich TJ. PMID: 37988251.

  3. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):443-452. Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. PMID: 36130191; PMCID: PMC9907485.

  4. Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr Open. 2022 Nov; 2. Huang L, Sok V, Aslam-Mir U, Marzan F, Whalen M, Rosenthal PJ, Aweeka F. PMID: 35531322; PMCID: PMC9068709.

  5. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. 2022 03 09; 13(1):1219. Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, Fehrman E, Pardons M, Kumar S, Deitchman AN, Ravanfar V, Schulte B, Wu IK, Pan T, Reeves JD, Nixon CC, Iyer NS, Torres L, Munter SE, Hyunh T, Petropoulos CJ, Hoh R, Franc BL, Gama L, Koup RA, Mascola JR, Chomont N, Deeks SG, VanBrocklin HF, Henrich TJ. PMID: 35264559; PMCID: PMC8907355.

  6. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. PLoS One. 2021; 16(3):e0247356. Sok V, Marzan F, Gingrich D, Aweeka F, Huang L. PMID: 33667247; PMCID: PMC7935301.

  7. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2021 05; 21(5):1765-1779. Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. PMID: 32780519; PMCID: PMC9177122.

  8. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):651-658. Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT, ACTG 5314 Protocol Team. PMID: 33177476; PMCID: PMC8132144.

  9. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 09 14; 67(7):1079-1088. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. PMID: 29547881; PMCID: PMC6137112.

  10. Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther. 2017 Sep;102(3):520-528. doi: 10.1002/cpt.664. Epub 2017 May 30. PMID: 28187497; PMCID: PMC5546920.

  11. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 08 01; 63(3):414-22. Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. PMID: 27143666; PMCID: PMC4946019.

  12. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal. 2013 Dec; 86:198-203. Huang L, Lizak P, Aweeka F, Long-Boyle J. PMID: 24013121; PMCID: PMC3835489.

  13. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29; 367(22):2110-8. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. PMID: 23190222; PMCID: PMC3664297.

  14. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012 Jan; 4(2):157-66. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. PMID: 22250798; PMCID: PMC3321395.

Aweeka

  1. A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models. Res Sq. 2023 Oct 23. Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN. PMID: 37961240; PMCID: PMC10635313.

  2. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. J Infect Dis. 2023 10 03; 228(7):926-935. Roh ME, Zongo I, Haro A, Huang L, Somé AF, Yerbanga RS, Conrad MD, Wallender E, Legac J, Aweeka F, Ouédraogo JB, Rosenthal PJ. PMID: 37221018; PMCID: PMC10547452.

  3. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention. Antimicrob Agents Chemother. 2023 04 18; 67(4):e0142722. Hong H, Aslam-Mir U, Kajubi R, Wallender E, Mwebaza N, Dorsey G, Rosenthal PJ, Aweeka FT, Huang L. PMID: 36916944; PMCID: PMC10112216.

  4. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):443-452. Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. PMID: 36130191; PMCID: PMC9907485.

  5. M. tuberculosis antigen-responsive IL17+ CD4 T cells are disproportionately spared in ART-suppressed HIV. bioRxiv. 2023 Jan 07. Ogongo P, Tran A, Marzan F, Gingrich D, Krone M, Aweeka F, Arlehamn CSL, Martin JN, Deeks SG, Hunt PW, Ernst JD. PMID: 36711855; PMCID: PMC9881994.

  6. Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL. HIV Med. 2023 06; 24(6):749-753. Rahman F, Brates I, Aweeka F, Bosch RJ, Deitchman A, Nixon D, Aberg JA. PMID: 36549898; PMCID: PMC10257730.

  7. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clin Pharmacol Ther. 2023 03; 113(3):660-669. Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz-Garcia A, Parikh S. PMID: 36260349; PMCID: PMC9981240.

  8. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. Clin Infect Dis. 2022 08 31; 75(3):406-415. Hughes E, Wallender E, Kajubi R, Jagannathan P, Ochieng T, Kakuru A, Kamya MR, Clark TD, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM. PMID: 34864925; PMCID: PMC9427153.

  9. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. J Chromatogr Open. 2022 Nov; 2. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. PMID: 35875822; PMCID: PMC9302610.

  10. Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr Open. 2022 Nov; 2. Huang L, Sok V, Aslam-Mir U, Marzan F, Whalen M, Rosenthal PJ, Aweeka F. PMID: 35531322; PMCID: PMC9068709.

  11. Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs. Commun Biol. 2022 01 27; 5(1):99. Bieber JM, Sanman LE, Sun X, Hammerlindl H, Bao F, Roth MA, Koleske ML, Huang L, Aweeka F, Wu LF, Altschuler SJ. PMID: 35087225; PMCID: PMC8795448.

  12. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Nat Commun. 2021 11 18; 12(1):6714. Wallender E, Ali AM, Hughes E, Kakuru A, Jagannathan P, Muhindo MK, Opira B, Whalen M, Huang L, Duvalsaint M, Legac J, Kamya MR, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. PMID: 34795281; PMCID: PMC8602248.

  13. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021 08 10; 36(6):109518. Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. PMID: 34358460; PMCID: PMC8342976.

  14. Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. J Infect Dis. 2021 05 20; 223(9):1621-1630. Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW. PMID: 32915986; PMCID: PMC8136975.

  15. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Pediatr Infect Dis J. 2021 05 01; 40(5):446-452. Owor M, Tierney C, Ziemba L, Browning R, Moye J, Graham B, Reding C, Costello D, Norman J, Wiesner L, Hughes E, Whalen ME, Purdue L, Mmbaga BT, Kamthunzi P, Kawalazira R, Nathoo K, Bradford S, Coletti A, Aweeka F, Musoke P. PMID: 33464021; PMCID: PMC8043511.

  16. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. PLoS One. 2021; 16(3):e0247356. Sok V, Marzan F, Gingrich D, Aweeka F, Huang L. PMID: 33667247; PMCID: PMC7935301.

  17. Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. medRxiv. 2021 Mar 01. Peluso MJ, Deitchman AN, Torres L, Iyer NS, Nixon CC, Munter SE, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman E, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. PMID: 33688685; PMCID: PMC7941662.

  18. Exposure to pesticides in utero impacts the fetal immune system and response to vaccination in infancy. Nat Commun. 2021 01 08; 12(1):132. Prahl M, Odorizzi P, Gingrich D, Muhindo M, McIntyre T, Budker R, Jagannathan P, Farrington L, Nalubega M, Nankya F, Sikyomu E, Musinguzi K, Naluwu K, Auma A, Kakuru A, Kamya MR, Dorsey G, Aweeka F, Feeney ME. PMID: 33420104; PMCID: PMC7794579.

  19. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):651-658. Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT, ACTG 5314 Protocol Team. PMID: 33177476; PMCID: PMC8132144.

  20. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. Antimicrob Agents Chemother. 2020 11 17; 64(12). Hughes E, Imperial M, Wallender E, Kajubi R, Huang L, Jagannathan P, Zhang N, Kakuru A, Natureeba P, Mwima MW, Muhindo M, Mwebaza N, Clark TD, Opira B, Nakalembe M, Havlir D, Kamya M, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM. PMID: 33020153; PMCID: PMC7674024.

  21. Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia. Am J Trop Med Hyg. 2020 12; 103(6):2224-2232. Ippolito MM, Pringle JC, Siame M, Katowa B, Aydemir O, Oluoch PO, Huang L, Aweeka FT, Bailey JA, Juliano JJ, Meshnick SR, Shapiro TA, Moss WJ, Thuma PE. PMID: 33078701; PMCID: PMC7695049.

  22. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2021 05; 21(5):1765-1779. Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. PMID: 32780519; PMCID: PMC9177122.

  23. Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations. PLoS One. 2020; 15(5):e0233893. Mwebaza N, Cheah V, Forsman C, Kajubi R, Marzan F, Wallender E, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. PMID: 32470030; PMCID: PMC7259774.

  24. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. Clin Pharmacol Ther. 2020 08; 108(2):253-263. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, Luetkemeyer AF, Savic RM. PMID: 32285930; PMCID: PMC7262072.

  25. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrob Agents Chemother. 2020 04 21; 64(5). Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. PMID: 32071050; PMCID: PMC7179577.

  26. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. Pharmacogenet Genomics. 2020 04; 30(3):45-53. Haas DW, Cramer YS, Godfrey C, Rosenkranz SL, Aweeka F, Berzins B, Coombs R, Coughlin K, Moran LE, Gingrich D, Zorrilla CD, Baker P, Cohn SE, Scarsi KK, AIDS Clinical Trials Group A5316 Study Team. PMID: 32106141; PMCID: PMC7398416.

  27. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):140-147. Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. PMID: 31929402; PMCID: PMC7061940.

  28. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Lancet HIV. 2019 09; 6(9):e601-e612. Scarsi KK, Cramer YS, Rosenkranz SL, Aweeka F, Berzins B, Coombs RW, Coughlin K, Moran LE, Zorrilla CD, Akelo V, Aziz M, Friedman RK, Gingrich D, Swaminathan S, Godfrey C, Cohn SE, AIDS Clinical Trials Group A5316 Study Team. PMID: 31498109; PMCID: PMC6765389.

  29. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Clin Pharmacol Ther. 2019 12; 106(6):1310-1318. Whalen ME, Kajubi R, Chamankhah N, Huang L, Orukan F, Wallender E, Kamya MR, Dorsey G, Jagannathan P, Rosenthal PJ, Mwebaza N, Aweeka FT. PMID: 31173649; PMCID: PMC6851416.

  30. Comparison on simultaneous caillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda. BMC Infect Dis. 2019 Jun 26; 19(1):559. Lehane A, Were M, Wade M, Hamadu M, Cahill M, Kiconco S, Kajubi R, Aweeka F, Mwebaza N, Li F, Parikh S. PMID: 31242863; PMCID: PMC6595677.

  31. High Kynurenine:Tryptophan Ratio Is Associated With Liver Fibrosis in HIV-Monoinfected and HIV/Hepatitis C Virus-Coinfected Women. Open Forum Infect Dis. 2019 Jul; 6(7):ofz281. Kardashian A, Ma Y, Yin MT, Scherzer R, Nolan O, Aweeka F, Tien PC, Price JC. PMID: 31304190; PMCID: PMC6612851.

  32. Determination of melphalan in human plasma by UPLC-UV method. Cancer Chemother Pharmacol. 2019 05; 83(5):905-910. Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J. PMID: 30847504; PMCID: PMC6490959.

  33. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda. Antimicrob Agents Chemother. 2019 02; 63(2). Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. PMID: 30530597; PMCID: PMC6355581.

  34. Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrob Agents Chemother. 2018 10; 62(10). Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P, WWARN Amodiaquine PK Study Group. PMID: 30038039; PMCID: PMC6153844.

  35. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 09 14; 67(7):1079-1088. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. PMID: 29547881; PMCID: PMC6137112.

  36. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS One. 2018; 13(8):e0202082. Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT. PMID: 30114201; PMCID: PMC6095545.

  37. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med. 2018 07; 15(7):e1002606. Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, Greenhouse B, Wallender E, Aweeka F, Prahl M, Charlebois ED, Feeney ME, Havlir DV, Kamya MR, Dorsey G. PMID: 30016328; PMCID: PMC6049882.

  38. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018 06; 15(6):e1002579. Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J. PMID: 29894518; PMCID: PMC5997317.

  39. Elevated plasma abscisic acid is associated with asymptomatic falciparum malaria and with IgG-/caspase-1-dependent immunity in Plasmodium yoelii-infected mice. Sci Rep. 2018 06 11; 8(1):8896. Glennon EKK, Megawati D, Torrevillas BK, Ssewanyana I, Huang L, Aweeka F, Greenhouse B, Adams LG, Luckhart S. PMID: 29891920; PMCID: PMC5995817.

  40. Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. J Anal Methods Chem. 2018; 2018:7965124. Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K. PMID: 29854560; PMCID: PMC5944200.

  41. Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS. J Pharm Biomed Anal. 2018 Jun 05; 155:241-246. Ippolito MM, Huang L, Siame M, Thuma P, Shapiro TA, Aweeka FT. PMID: 29655094; PMCID: PMC5949273.

  42. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018 03 05; 217(6):964-972. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM. PMID: 29272443; PMCID: PMC5853566.

  43. Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction". Clin Pharmacol Ther. 2018 04; 103(4):571. Jagannathan P, Kajubi R, Aweeka FT. PMID: 29322501; PMCID: PMC5847448.

  44. Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017 11 15; 216(8):1008-1017. Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. PMID: 28968782; PMCID: PMC5853776.

  45. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS One. 2017; 12(10):e0186589. Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT, IMPAACT P1079 protocol team. PMID: 29065172; PMCID: PMC5655345.

  46. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1701-1713. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. PMID: 28684371; PMCID: PMC6108324.

  47. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther. 2017 Sep; 102(3):520-528. Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT. PMID: 28187497; PMCID: PMC5546920.

  48. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect Dis. 2017; 4(1):ofw278. O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA. PMID: 28480270; PMCID: PMC5414028.

  49. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis. 2016 Oct; 3(4):ofw217. Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S. PMID: 28018925; PMCID: PMC5170492.

  50. Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. J Infect Dis. 2016 Oct 15; 214(8):1243-51. Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, Muhindo M, Creek DJ, Sukumar N, Blessborn D, Tappero JW, Kakuru A, Bergqvist Y, Aweeka FT, Parikh S. PMID: 27471317; PMCID: PMC5034953.

  51. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 08 01; 63(3):414-22. Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. PMID: 27143666; PMCID: PMC4946019.

  52. Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10. J Infect Dis. 2016 07 15; 214(2):329-38. Jagannathan P, Bowen K, Nankya F, McIntyre TI, Auma A, Wamala S, Sikyomu E, Naluwu K, Nalubega M, Boyle MJ, Farrington LA, Bigira V, Kapisi J, Aweeka F, Greenhouse B, Kamya M, Dorsey G, Feeney ME. PMID: 27067196; PMCID: PMC4918829.

  53. Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):137-45. Weinberg A, Park JG, Bosch R, Cho A, Livingston E, Aweeka F, Cramer Y, Watts DH, Luque AE, Cohn SE. PMID: 26413850; PMCID: PMC4712075.

  54. Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results. J Acquir Immune Defic Syndr. 2015 Dec 15; 70(5):510-4. Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC. PMID: 26230332; PMCID: PMC4648657.

  55. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1274-82. Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N. PMID: 26666942; PMCID: PMC4775973.

  56. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar J. 2015 Sep 24; 14:368. Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F. PMID: 26403465; PMCID: PMC4582734.

  57. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother. 2015 Dec; 59(12):7852-6. Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK. PMID: 26392500; PMCID: PMC4649208.

  58. PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150. Jacobs J AIDS HIV. 2015; 1(1). Sha BE, Tierney C, Sun X, Stek A, Cohn SE, Coombs RW, Bastow B, Aweeka FT, AIDS Clinical Trials Group (ACTG) 5153s Team. PMID: 26878071; PMCID: PMC4749161.

  59. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria. Clin Pharmacol Ther. 2015 Jul; 98(1):87-95. Sambol NC, Yan L, Creek DJ, McCormack SA, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero JW, Lindegardh N, Tarning J, Nosten F, Aweeka FT, Parikh S. PMID: 25732044; PMCID: PMC5088713.

  60. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51. Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS, AIDS Clinical Trials Group (ACTG) A5257 Team. PMID: 25767256; PMCID: PMC4660025.

  61. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. PMID: 25742090; PMCID: PMC4351793.

  62. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015 Apr; 59(4):2094-101. Luque AE, Cohn SE, Park JG, Cramer Y, Weinberg A, Livingston E, Klingman KL, Aweeka F, Watts DH. PMID: 25624326; PMCID: PMC4356823.

  63. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 01; 67(4):375-81. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M, IMPAACT 1026s study team. PMID: 25162818; PMCID: PMC4213295.

  64. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28; 28(18):2701-9. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. PMID: 25493596; PMCID: PMC4487368.

  65. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Tea. PMID: 25407158; PMCID: PMC4320673.

  66. Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2014 Oct 07; 161(7):I-22. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team. PMID: 25285557.

  67. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team. PMID: 25285539; PMCID: PMC4412467.

  68. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug; 11(8):e1001689. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. PMID: 25093754; PMCID: PMC4122345.

  69. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep; 58(9):5245-52. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW, AIDS Clinical Trials Group A5306 Study Team. PMID: 24957823; PMCID: PMC4135849.

  70. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. PMID: 24861874; PMCID: PMC4104812.

  71. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 01; 960:194-9. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. PMID: 24820973; PMCID: PMC4110960.

  72. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother. 2014 May; 69(5):1370-6. Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S. PMID: 24446424; PMCID: PMC3977609.

  73. Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS. Bioanalysis. 2014; 6(23):3081-9. Kjellin LL, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. PMID: 25529877; PMCID: PMC4321809.

  74. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. PMID: 24038035; PMCID: PMC3933454.

  75. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal. 2013 Dec; 86:198-203. Huang L, Lizak P, Aweeka F, Long-Boyle J. PMID: 24013121; PMCID: PMC3835489.

  76. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):578-84. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D, Prevention of Malaria and HIV disease in Tororo (PROMOTE) study. PMID: 24135775; PMCID: PMC3800282.

  77. Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care. 2013 Nov-Dec; 12(6):375-7. Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF. PMID: 23881910; PMCID: PMC4100473.

  78. Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method. Bioanalysis. 2013 Jun; 5(12):1501-6. Huang L, Olson A, Gingrich D, Aweeka FT. PMID: 23795928; PMCID: PMC3879143.

  79. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013 Jun 01; 63(2):184-8. Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka FT, Levy JA. PMID: 23392464; PMCID: PMC3653990.

  80. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Study Team. PMID: 23592830; PMCID: PMC3719885.

  81. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis. 2013 Oct; 17(10):e857-61. Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ. PMID: 23587599; PMCID: PMC3776002.

  82. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013 Jun; 57(6):2780-7. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. PMID: 23571542; PMCID: PMC3716161.

  83. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis. 2013 Jun 01; 207(11):1646-54. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. PMID: 23447696; PMCID: PMC4318925.

  84. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb; 56(4):598-605. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV, SEARCH Collaboration. PMID: 23243180; PMCID: PMC3552523.

  85. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29; 367(22):2110-8. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. PMID: 23190222; PMCID: PMC3664297.

  86. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):310-6. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. PMID: 22918158; PMCID: PMC3511816.

  87. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012 Oct; 56(10):5374-80. Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. PMID: 22869579; PMCID: PMC3457371.

  88. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. PMID: 22671777; PMCID: PMC5087332.

  89. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012 Apr 24; 26(7):833-41. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT, AIDS Clinical Trials Group Study 5208 Team. PMID: 22301417; PMCID: PMC3506024.

  90. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012 Apr 15; 59(5):455-62. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C, ACTG 5267 Study Team. PMID: 22126739; PMCID: PMC3302922.

  91. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012; 2012:703604. Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT. PMID: 22500218; PMCID: PMC3303559.

  92. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012 Jan; 4(2):157-66. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. PMID: 22250798; PMCID: PMC3321395.

  93. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011 Jan-Feb; 12(1):9-23. Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, Kalams SA, Aweeka FT, Bastow B, Bardeguez A, Kmack A, Stek A, Aids Clinical Trials Group ACTG A5150 Team. PMID: 21388937; PMCID: PMC3227722.

  94. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):473-82. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE. PMID: 20842042; PMCID: PMC4197050.

  95. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):361-4. Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. PMID: 20595906; PMCID: PMC3164483.

  96. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):285-9. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. PMID: 19890215; PMCID: PMC3119357.

  97. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010 May 19; 2(32):32ra36. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. PMID: 20484731; PMCID: PMC3034445.

  98. A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. Anal Chem Insights. 2010 Mar 29; 5:15-23. Huang L, Lizak PS, Jayewardene AL, Marzan F, Lee MN, Aweeka FT. PMID: 20448843; PMCID: PMC2865164.

  99. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS. 2010 Jan 16; 24(2):265-70. Pao VY, Lee GA, Taylor S, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. PMID: 19890203.

  100. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Tea. PMID: 20002783; PMCID: PMC2874627.

  101. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010 Jan; 54(1):52-9. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka F. PMID: 19841149; PMCID: PMC2798532.

  102. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One. 2009 Sep 01; 4(9):e6877. Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. PMID: 19721718; PMCID: PMC2731205.

  103. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):424-9. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. PMID: 19506482.

  104. Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma. J Pharm Biomed Anal. 2009 Dec 05; 50(5):959-65. Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT. PMID: 19646837; PMCID: PMC3034030.

  105. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009 Jun; 53(6):2335-41. Eron JJ, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD, ACTG5126 Study Team. PMID: 19307363; PMCID: PMC2687257.

  106. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):285-90. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. PMID: 19112051; PMCID: PMC3032609.

  107. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008 Aug 01; 47(3):421-4. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. PMID: 18558886; PMCID: PMC2586907.

  108. Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX. J Acquir Immune Defic Syndr. 2008 May 01; 48(1):114-6. Venhoff N, Venhoff AC, Jayewardene AL, Aweeka F, Lebrecht D, Walker UA. PMID: 18438180.

  109. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M, PACTG 1026S Study Team, PACTG P1022 Study Team. PMID: 18366444; PMCID: PMC2755564.

  110. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008; 47(2):91-102. German PI, Aweeka FT. PMID: 18193915.

  111. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007 Oct 18; 21(16):2183-90. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. PMID: 18090045; PMCID: PMC3167072.

  112. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18; 21(16):2191-9. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. PMID: 18090046.

  113. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med. 2007 Jul; 8(5):288-94. Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT, AIDS Clinical Trials Group 5092s Study Team. PMID: 17561874.

  114. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15; 44(6):889-91. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. PMID: 17304470.

  115. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS. 2006 Sep 11; 20(14):1833-41. Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH, NIAID AIDS Clinical Trials Group. PMID: 16954724.

  116. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006 Sep 01; 43(5):658-60. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. PMID: 16886163; PMCID: PMC3205942.

  117. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials. 2006 May-Jun; 7(3):142-53. McGee B, Smith N, Aweeka F. PMID: 16880170.

  118. Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions. HIV Med. 2006 Mar; 7(2):122-8. Motoya T, Thevanayagam LN, Blaschke TF, Au S, Stone JA, Jayewardene AL, Chi J, Aweeka FT. PMID: 16420257.

  119. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 01; 192(9):1537-44. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. PMID: 16206068.

  120. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clin Trials. 2005 Sep-Oct; 6(5):246-53. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. PMID: 16306031.

  121. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB, AACTG 266 Team. PMID: 15498605.

  122. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004 Mar 05; 18(4):641-9. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. PMID: 15090769; PMCID: PMC3166345.

  123. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004; 44:499-523. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. PMID: 14744256.

  124. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther. 2003 Dec; 74(6):569-80. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB, Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators. PMID: 14663459.

  125. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003 Sep; 112(3 Pt 1):e220-7. Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT, Pediatric AIDS Clinical Trials Group 377 Protocol Team. PMID: 12949316.

  126. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003 Aug 19; 139(4):258-66. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. PMID: 12965981.

  127. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003 May 23; 17(8):1195-9. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. PMID: 12819521.

  128. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. J Pharm Biomed Anal. 2003 Apr 01; 31(5):953-9. Chi J, Jayewardene AL, Stone JA, Aweeka FT. PMID: 12684107.

  129. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis. 2002 May 01; 185(9):1359-63. Wohl DA, Aweeka FT, Schmitz J, Pomerantz R, Cherng DW, Spritzler J, Fox L, Simpson D, Bell D, Holohan MK, Thomas S, Robinson W, Kaplan G, Teppler H, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group 267. PMID: 12001058.

  130. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002 Mar 08; 16(4):543-50. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI. PMID: 11872997.

  131. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002 Mar 08; 16(4):569-77. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group. PMID: 11873000.

  132. A direct determination of thymidine triphosphate concentrations without dephosphorylation in peripheral blood mononuclear cells by LC/MS/MS. J Pharm Biomed Anal. 2001 Dec; 26(5-6):829-36. Chi J, Jayewardene A, Stone J, Gambertoglio JG, Aweeka FT. PMID: 11600294.

  133. An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma. J Pharm Biomed Anal. 2001 May; 25(2):309-17. Jayewardene AL, Kearney B, Stone JA, Gambertoglio JG, Aweeka FT. PMID: 11275438.

  134. Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study. Eur J Pharm Sci. 2001 Feb; 12(4):377-85. Zhang L, Price R, Aweeka F, Bellibas SE, Sheiner LB. PMID: 11231104.

  135. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. BioDrugs. 2000 Dec; 14(6):355-69. Tsunoda SM, Aweeka FT. PMID: 18034579.

  136. Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women. J Pharm Biomed Anal. 2000 Sep; 23(4):629-35. Homma M, Beckerman K, Hayashi S, Jayewardene AL, Oka K, Gambertoglio JG, Aweeka FT. PMID: 10975239.

  137. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000 May 26; 14(8):1061-2. Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT. PMID: 10853990.

  138. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol. 2000; 49 Suppl 1:27S-33S. Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RZ. PMID: 10771451; PMCID: PMC2015058.

  139. Drug interactions of antiretroviral agents. AIDS Clin Rev. 2000-2001; 193-227. Kosel BW, Aweeka F. PMID: 10999221.

  140. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob Agents Chemother. 1999 Nov; 43(11):2716-9. Homma M, Jayewardene AL, Gambertoglio J, Aweeka F. PMID: 10543752; PMCID: PMC89548.

  141. The penetration of anti-infectives into the central nervous system. Neurol Clin. 1999 Nov; 17(4):883-900. Kearney BP, Aweeka FT. PMID: 10517933.

  142. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. J Clin Pharmacol. 1999 Oct; 39(10):1085-93. Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F. PMID: 10516944.

  143. Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr. 1999 Aug 15; 21(5):384-95. Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. PMID: 10458619.

  144. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999 Jun 18; 13(9):1051-61. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. PMID: 10397535.

  145. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia. 1999 Jun; 40(6):777-82. Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Alldredge BK. PMID: 10368078.

  146. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 01; 20(4):350-7. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG. PMID: 10096579.

  147. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 01; 20(1):39-43. Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, Novakovic-Agopian T, Price RW. PMID: 9928728.

  148. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999 Jan; 65(1):21-8. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. PMID: 9951427.

  149. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B Biomed Sci Appl. 1998 Apr 10; 707(1-2):203-11. Jayewardene AL, Zhu F, Aweeka FT, Gambertoglio JG. PMID: 9613951.

  150. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration? Clin Ther. 1998 Mar-Apr; 20(2):232-43. Aweeka FT, Brody SR, Jacobson M, Botwin K, Martin-Munley S. PMID: 9589815.

  151. Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. Int J Antimicrob Agents. 1997 Sep; 9(2):131-5. Brody SR, Aweeka FT. PMID: 18611830.

  152. Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy. 1997 May-Jun; 17(3):591-8. Wolfe EJ, Mathur V, Tomlanovich S, Jung D, Wong R, Griffy K, Aweeka FT. PMID: 9165564.

  153. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine. J Clin Pharmacol. 1996 Dec; 36(12):1107-13. Aweeka FT, Kwong M, Mak M, al-Uzri A, Affrime M, Cutler D, Kahn J, Gambertoglio JG. PMID: 9013366.

  154. Disposition of foscarnet during peritoneal dialysis. Ann Pharmacother. 1996 Oct; 30(10):1106-9. Alexander AC, Akers A, Matzke GR, Aweeka FT, Fraley DS. PMID: 8893116.

  155. Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. AIDS. 1996 Sep; 10(10):1113-9. Drusano GL, Aweeka F, Gambertoglio J, Jacobson M, Polis M, Lane HC, Eaton C, Martin-Munley S. PMID: 8874628.

  156. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet. 1996 Feb; 30(2):107-40. Tsunoda SM, Aweeka FT. PMID: 8906895.

  157. Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation. J Clin Pharmacol. 1995 Oct; 35(10):967-73. d'Uscio CH, Aweeka FT, Prueksaritanont T, Tomlanovich SJ, Gupta SK, Lantz MV, Gambertoglio JG, Garovoy MR, Benet LZ. PMID: 8568014.

  158. Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. J Clin Pharmacol. 1995 Sep; 35(9):856-64. Aweeka FT, Mak M, al-Uzri A, Peter K, Dett C, Franco J, Affrime M, Guerciolini R, Cutler DL, Kahn J, et al. PMID: 8786245.

  159. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Clin Pharmacol Ther. 1995 Apr; 57(4):403-12. Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA. PMID: 7712668.

  160. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol. 1994 Jan; 34(1):60-7. Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ. PMID: 8132853.

  161. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother. 1992 Aug; 36(8):1773-8. Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. PMID: 1416864; PMCID: PMC192046.

  162. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991 May; 72(5):1130-5. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. PMID: 1827127.

  163. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990 Jan 26; 525(1):133-40. Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG. PMID: 2140113.

  164. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May; 33(5):742-5. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. PMID: 2546491; PMCID: PMC172525.

  165. Interleukin-2 and immunoglobulin increases with H2-antagonists in humans. Transplant Proc. 1989 Feb; 21(1 Pt 2):1718-21. Aweeka F, Lizak P, Garovoy M, Amend W, Birnbaum J, Gumbert M, Gambertoglio J. PMID: 2523589.

  166. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct; 158(4):862-5. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. PMID: 2844921.

Deitchman

  1. The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms. J Med Virol. 2023 Nov; 95(11):e29216. Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Bodansky A, Kung A, Hoh R, Williams MC, Kerbleski M, Maison DP, Deveau TM, Munter SE, Lombardo J, Wrin T, Petropoulos CJ, Durstenfeld MS, Hsue PY, Kelly JD, Greenhouse B, Martin JN, Deeks SG, Peluso MJ, Henrich TJ. PMID: 37988251.

  2. A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models. Res Sq. 2023 Oct 23. Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN. PMID: 37961240; PMCID: PMC10635313.

  3. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J. 2023 08; 62(2). Ernest JP, Goh JJN, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. PMID: 37321622; PMCID: PMC10469274.

  4. Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies. Viruses. 2023 05 09; 15(5). Buck AM, Deveau TM, Henrich TJ, Deitchman AN. PMID: 37243212; PMCID: PMC10222761.

  5. The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms. medRxiv. 2023 Mar 31. Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Hoh R, Williams MC, Kerbleski M, Deveau TM, Munter SE, Lombardo J, Wrin T, Petropoulos CJ, Durstenfeld MS, Hsue PY, Kelly JD, Greenhouse B, Martin JN, Deeks SG, Peluso MJ, Henrich TJ. PMID: 37034660; PMCID: PMC10081395.

  6. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023; 14:1129459. Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, Fine J, Fontelo P, Kim AY, Shaw G, Stratford J, Ceger P, Costantine MM, Fisher L, O'Brien L, Maughan C, Quigley JG, Gabbay V, Mohandas S, Williams D, McComsey GA. PMID: 36969241; PMCID: PMC10034329.

  7. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023 02 01; 133(3). Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, Chan F, Lu S, Goldberg SA, Hoh R, Tai V, Torres L, Iyer NS, Deswal M, Ngo LH, Buitrago M, Rodriguez A, Chen JY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deitchman AN, Hellmuth J, Spinelli MA, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Deeks SG, Hunt PW, Henrich TJ. PMID: 36454631; PMCID: PMC9888380.

  8. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. bioRxiv. 2023 Jan 20. Ernest JP, Ni Goh JJ, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. PMID: 36711493; PMCID: PMC9882354.

  9. Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL. HIV Med. 2023 06; 24(6):749-753. Rahman F, Brates I, Aweeka F, Bosch RJ, Deitchman A, Nixon D, Aberg JA. PMID: 36549898; PMCID: PMC10257730.

  10. Female Genital Fibroblasts Diminish the In Vitro Efficacy of PrEP against HIV. Viruses. 2022 08 04; 14(8). George AF, McGregor M, Gingrich D, Neidleman J, Marquez RS, Young KC, Thanigaivelan KL, Greene WC, Tien PC, Deitchman AN, Spitzer TL, Roan NR. PMID: 36016345; PMCID: PMC9413545.

  11. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. 2022 03 09; 13(1):1219. Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, Fehrman E, Pardons M, Kumar S, Deitchman AN, Ravanfar V, Schulte B, Wu IK, Pan T, Reeves JD, Nixon CC, Iyer NS, Torres L, Munter SE, Hyunh T, Petropoulos CJ, Hoh R, Franc BL, Gama L, Koup RA, Mascola JR, Chomont N, Deeks SG, VanBrocklin HF, Henrich TJ. PMID: 35264559; PMCID: PMC8907355.

  12. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021 08 10; 36(6):109518. Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. PMID: 34358460; PMCID: PMC8342976.

  13. Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infect Dis. 2021 Aug; 8(8):ofab393. Peluso MJ, Munter SE, Lynch KL, Yun C, Torres L, Iyer NS, Donatelli J, Ryan L, Deitchman AN, Deeks SG, Rutishauser RL, Henrich TJ. PMID: 34395717; PMCID: PMC8344490.

  14. Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. J Infect Dis. 2021 06 04; 223(11):1855-1864. Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic RM, Nuermberger EL. PMID: 31993638; PMCID: PMC8176636.

  15. Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. J Infect Dis. 2021 05 20; 223(9):1621-1630. Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW. PMID: 32915986; PMCID: PMC8136975.

  16. Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. medRxiv. 2021 Mar 01. Peluso MJ, Deitchman AN, Torres L, Iyer NS, Nixon CC, Munter SE, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman E, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. PMID: 33688685; PMCID: PMC7941662.

  17. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):651-658. Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT, ACTG 5314 Protocol Team. PMID: 33177476; PMCID: PMC8132144.

  18. Supporting Precision Dosing in Drug Labeling. Clin Pharmacol Ther. 2021 01; 109(1):37-41. Neely M, Onufrak N, Scheetz MH, Avedissian S, Lakota E, Deitchman AN, Gonzalez D. PMID: 33111328.

  19. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2021 05; 21(5):1765-1779. Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. PMID: 32780519; PMCID: PMC9177122.

  20. The Risk of Treating Populations Instead of Patients. CPT Pharmacometrics Syst Pharmacol. 2019 05; 8(5):256-258. Deitchman AN. PMID: 30884214; PMCID: PMC6539720.

  21. Nonlinear Protein Binding: Not What You Think. J Pharm Sci. 2018 07; 107(7):1754-1760. Deitchman AN, Singh RSP, Derendorf H. PMID: 29626534; PMCID: PMC6042850.

  22. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854. McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA. PMID: 29650764; PMCID: PMC5901893.

  23. Enhanced in vitro activity of tigecycline in the presence of chelating agents. Int J Antimicrob Agents. 2018 May; 51(5):799-802. Deitchman AN, Singh RSP, Rand KH, Derendorf H. PMID: 29305959; PMCID: PMC5940551.

  24. A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. Int J Antimicrob Agents. 2017 Apr; 49(4):449-455. Singh RSP, Mukker JK, Drescher SK, Deitchman AN, Derendorf H. PMID: 28237830.

  25. Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization. AAPS J. 2017 03; 19(2):334-342. Deitchman AN, Heinrichs MT, Khaowroongrueng V, Jadhav SB, Derendorf H. PMID: 27943149.

  26. Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Rev Anti Infect Ther. 2016; 14(11):997-1006. Deitchman A, de Jong D, Barbour A, Derendorf H. PMID: 27690689.

  27. Role of Divalent Metal Ions in Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline. J Pharm Sci. 2016 11; 105(11):3409-3414. Singh RSP, Mukker JK, Deitchman AN, Drescher SK, Derendorf H. PMID: 27616672.

  28. Measuring drug distribution in the critically ill patient. Adv Drug Deliv Rev. 2014 Nov 20; 77:22-6. Deitchman AN, Derendorf H. PMID: 25194997.

  29. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis. 2014 Feb 01; 2(1):17-42. B?dingen FV, Gonzalez D, Tucker AN, Derendorf H. PMID: 24949199; PMCID: PMC4059611.

Huang

  1. Pharmacokinetics (PK) of Deferasirox in Transfusion Dependent Thalassemia. Blood. 2023 Nov 28; 142(Supplement 1):5248. Winger WB, Usac UF, Huang HL, Lal LA, Long-Boyle LJ.

  2. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention. Antimicrob Agents Chemother. 2023 04 18; 67(4):e0142722. Hong H, Aslam-Mir U, Kajubi R, Wallender E, Mwebaza N, Dorsey G, Rosenthal PJ, Aweeka FT, Huang L. PMID: 36916944; PMCID: PMC10112216.

  3. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):443-452. Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. PMID: 36130191; PMCID: PMC9907485.

  4. Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation. Pharmaceutics. 2022 Nov 15; 14(11). Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, Long S, Gupta AO, Horn B, Lamba JK, Huang L, Apsel-Winger B, Keizer RJ, Savic R, Long-Boyle J. PMID: 36432661.

  5. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clin Pharmacol Ther. 2023 03; 113(3):660-669. Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz-Garcia A, Parikh S. PMID: 36260349; PMCID: PMC9981240.

  6. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. J Chromatogr Open. 2022 Nov; 2. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. PMID: 35875822; PMCID: PMC9302610.

  7. Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr Open. 2022 Nov; 2. Huang L, Sok V, Aslam-Mir U, Marzan F, Whalen M, Rosenthal PJ, Aweeka F. PMID: 35531322; PMCID: PMC9068709.

  8. Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs. Commun Biol. 2022 01 27; 5(1):99. Bieber JM, Sanman LE, Sun X, Hammerlindl H, Bao F, Roth MA, Koleske ML, Huang L, Aweeka F, Wu LF, Altschuler SJ. PMID: 35087225; PMCID: PMC8795448.

  9. Loss of GdpP Function in Staphylococcus aureus Leads to β-Lactam Tolerance and Enhanced Evolution of β-Lactam Resistance. Antimicrob Agents Chemother. 2022 02 15; 66(2):e0143121. Poon R, Basuino L, Satishkumar N, Chatterjee A, Mukkayyan N, Buggeln E, Huang L, Nair V, Argudín MA, Datta SK, Chambers HF, Chatterjee SS. PMID: 34843389; PMCID: PMC8846394.

  10. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. Nat Commun. 2021 11 18; 12(1):6714. Wallender E, Ali AM, Hughes E, Kakuru A, Jagannathan P, Muhindo MK, Opira B, Whalen M, Huang L, Duvalsaint M, Legac J, Kamya MR, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. PMID: 34795281; PMCID: PMC8602248.

  11. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. PLoS One. 2021; 16(3):e0247356. Sok V, Marzan F, Gingrich D, Aweeka F, Huang L. PMID: 33667247; PMCID: PMC7935301.

  12. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):651-658. Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT, ACTG 5314 Protocol Team. PMID: 33177476; PMCID: PMC8132144.

  13. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. Antimicrob Agents Chemother. 2020 11 17; 64(12). Hughes E, Imperial M, Wallender E, Kajubi R, Huang L, Jagannathan P, Zhang N, Kakuru A, Natureeba P, Mwima MW, Muhindo M, Mwebaza N, Clark TD, Opira B, Nakalembe M, Havlir D, Kamya M, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM. PMID: 33020153; PMCID: PMC7674024.

  14. Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia. Am J Trop Med Hyg. 2020 12; 103(6):2224-2232. Ippolito MM, Pringle JC, Siame M, Katowa B, Aydemir O, Oluoch PO, Huang L, Aweeka FT, Bailey JA, Juliano JJ, Meshnick SR, Shapiro TA, Moss WJ, Thuma PE. PMID: 33078701; PMCID: PMC7695049.

  15. Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations. PLoS One. 2020; 15(5):e0233893. Mwebaza N, Cheah V, Forsman C, Kajubi R, Marzan F, Wallender E, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. PMID: 32470030; PMCID: PMC7259774.

  16. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):140-147. Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. PMID: 31929402; PMCID: PMC7061940.

  17. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Clin Pharmacol Ther. 2019 12; 106(6):1310-1318. Whalen ME, Kajubi R, Chamankhah N, Huang L, Orukan F, Wallender E, Kamya MR, Dorsey G, Jagannathan P, Rosenthal PJ, Mwebaza N, Aweeka FT. PMID: 31173649; PMCID: PMC6851416.

  18. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1603-1610. Wang H, Jones AK, Dvorak CC, Huang L, Orchard P, Ivaturi V, Long-Boyle J. PMID: 31002993; PMCID: PMC10291704.

  19. Determination of melphalan in human plasma by UPLC-UV method. Cancer Chemother Pharmacol. 2019 05; 83(5):905-910. Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J. PMID: 30847504; PMCID: PMC6490959.

  20. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 09 14; 67(7):1079-1088. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. PMID: 29547881; PMCID: PMC6137112.

  21. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS One. 2018; 13(8):e0202082. Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT. PMID: 30114201; PMCID: PMC6095545.

  22. Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. J Anal Methods Chem. 2018; 2018:7965124. Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K. PMID: 29854560; PMCID: PMC5944200.

  23. Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS. J Pharm Biomed Anal. 2018 Jun 05; 155:241-246. Ippolito MM, Huang L, Siame M, Thuma P, Shapiro TA, Aweeka FT. PMID: 29655094; PMCID: PMC5949273.

  24. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018 03 05; 217(6):964-972. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM. PMID: 29272443; PMCID: PMC5853566.

  25. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. J Antimicrob Chemother. 2017 Dec 01; 72(12):3357-3365. Haagensen J, Verotta D, Huang L, Engel J, Spormann AM, Yang K. PMID: 28961810; PMCID: PMC5890705.

  26. Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017 11 15; 216(8):1008-1017. Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. PMID: 28968782; PMCID: PMC5853776.

  27. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS One. 2017; 12(10):e0186589. Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT, IMPAACT P1079 protocol team. PMID: 29065172; PMCID: PMC5655345.

  28. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1701-1713. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. PMID: 28684371; PMCID: PMC6108324.

  29. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis. 2016 Oct; 3(4):ofw217. Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S. PMID: 28018925; PMCID: PMC5170492.

  30. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 08 01; 63(3):414-22. Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. PMID: 27143666; PMCID: PMC4946019.

  31. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1274-82. Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N. PMID: 26666942; PMCID: PMC4775973.

  32. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar J. 2015 Sep 24; 14:368. Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F. PMID: 26403465; PMCID: PMC4582734.

  33. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother. 2015 Dec; 59(12):7852-6. Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK. PMID: 26392500; PMCID: PMC4649208.

  34. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015 Sep 18; 13:227. WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group. PMID: 26381375; PMCID: PMC4574542.

  35. New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms. Antimicrob Agents Chemother. 2015 Jul; 59(7):4074-81. Haagensen JA, Verotta D, Huang L, Spormann A, Yang K. PMID: 25918138; PMCID: PMC4468651.

  36. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28; 28(18):2701-9. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. PMID: 25493596; PMCID: PMC4487368.

  37. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Tea. PMID: 25407158; PMCID: PMC4320673.

  38. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug; 11(8):e1001689. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. PMID: 25093754; PMCID: PMC4122345.

  39. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. PMID: 24861874; PMCID: PMC4104812.

  40. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 01; 960:194-9. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. PMID: 24820973; PMCID: PMC4110960.

  41. Plasma and Intracellular Population Pharmacokinetic Analysis of Fludarabine in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s30. Long-Boyle LJ, Sambol SN, Dvorak DC, Cowan CM, Lee LS, Huang HL, Horn HB, Stricherz SM, Tolar TJ, Orchard OP, Jacobson JP, Aweeka AF.

  42. Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS. Bioanalysis. 2014; 6(23):3081-9. Kjellin LL, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. PMID: 25529877; PMCID: PMC4321809.

  43. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal. 2013 Dec; 86:198-203. Huang L, Lizak P, Aweeka F, Long-Boyle J. PMID: 24013121; PMCID: PMC3835489.

  44. Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method. Bioanalysis. 2013 Jun; 5(12):1501-6. Huang L, Olson A, Gingrich D, Aweeka FT. PMID: 23795928; PMCID: PMC3879143.

  45. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013 Jun 01; 63(2):184-8. Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka FT, Levy JA. PMID: 23392464; PMCID: PMC3653990.

  46. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis. 2013 Oct; 17(10):e857-61. Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ. PMID: 23587599; PMCID: PMC3776002.

  47. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):310-6. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. PMID: 22918158; PMCID: PMC3511816.

  48. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. PMID: 22671777; PMCID: PMC5087332.

  49. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012 Jan; 4(2):157-66. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. PMID: 22250798; PMCID: PMC3321395.

  50. An Interim Evaluation of Systemic F-Ara-a Exposure in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients Using An Optimal Sampling Design. Blood. 2011 Nov 18; 118(21):1962-1962. Long-Boyle LJ, Yan YS, Dvorak DC, Horn HB, Cowan CM, Huang HL, Sambol SN, Musick ML, Aweeka AF.

  51. A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. Anal Chem Insights. 2010 Mar 29; 5:15-23. Huang L, Lizak PS, Jayewardene AL, Marzan F, Lee MN, Aweeka FT. PMID: 20448843; PMCID: PMC2865164.

  52. Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma. J Pharm Biomed Anal. 2009 Dec 05; 50(5):959-65. Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT. PMID: 19646837; PMCID: PMC3034030.

  53. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):285-90. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. PMID: 19112051; PMCID: PMC3032609.

  54. Arthromyces ramosus peroxidase produces two chlorinating species. Biochem Biophys Res Commun. 2007 Apr 06; 355(2):581-6. Huang L, Ortiz de Montellano PR. PMID: 17303078; PMCID: PMC1852486.

  55. Different protein-binding selectivities for N-acyl heparin derivatives having N-phenylacetyl and heterocycle analogs of N-phenylacetyl substituted in place of N-sulfo groups. Bioorg Med Chem Lett. 2007 Jan 15; 17(2):419-23. Huang L, Fernández C, Kerns RJ. PMID: 17070049.

  56. Role of heme-protein covalent bonds in mammalian peroxidases. Protection of the heme by a single engineered heme-protein link in horseradish peroxidase. J Biol Chem. 2006 Jul 14; 281(28):18983-8. Huang L, Wojciechowski G, Ortiz de Montellano PR. PMID: 16651262.

  57. Heme-protein covalent bonds in peroxidases and resistance to heme modification during halide oxidation. Arch Biochem Biophys. 2006 Feb 01; 446(1):77-83. Huang L, Ortiz de Montellano PR. PMID: 16375846.

  58. Diversity-oriented chemical modification of heparin: Identification of charge-reduced N-acyl heparin derivatives having increased selectivity for heparin-binding proteins. Bioorg Med Chem. 2006 Apr 01; 14(7):2300-13. Huang L, Kerns RJ. PMID: 16314105.

  59. Autocatalytic modification of the prosthetic heme of horseradish but not lactoperoxidase by thiocyanate oxidation products. A role for heme-protein covalent cross-linking. J Am Chem Soc. 2005 Nov 16; 127(45):15871-9. Wojciechowski G, Huang L, Ortiz de Montellano PR. PMID: 16277530.

  60. Prosthetic heme modification during halide ion oxidation. Demonstration of chloride oxidation by horseradish peroxidase. J Am Chem Soc. 2005 Apr 20; 127(15):5345-53. Huang L, Wojciechowski G, Ortiz de Montellano PR. PMID: 15826172.

  61. Oxidation of carboxylic acids by horseradish peroxidase results in prosthetic heme modification and inactivation. J Am Chem Soc. 2004 Oct 13; 126(40):12865-73. Huang L, Colas C, Ortiz de Montellano PR. PMID: 15469283.

  62. Human heme oxygenase oxidation of 5- and 15-phenylhemes. J Biol Chem. 2004 Oct 08; 279(41):42593-604. Wang J, Niemevz F, Lad L, Huang L, Alvarez DE, Buldain G, Poulos TL, de Montellano PR. PMID: 15297453.

  63. Computer-aided molecular design of HIV-1 protease dissociative inhibitors. Acta Pharmaceutica Sinica (YaoXueXueBao). 1999; (5):353-357. Huang L, Tao G, Li L, Chi H.

  64. Method for determination of total mercury in foods by atomic fluorescence spectrometry. J. Chinese Food Hygiene. 1997; (1):3-5. Huang L, Yang H.

  65. Monitoring of lead content in foodstuff in China. J. Chinese Preventive Medicine. 1995; 29:96-98. Yang H, Zou Z, Jin C, Yi F, Liang C, Xu X, Wang X, Huang, L.

  66. Study on the tolerance limit for nitrite in Chinese foods. Hygiene Research. 1995; 24:176-178. Yang H, Huang L, Xie B.

  67. Survey of mercury contamination of food in some areas of China. J. Hygiene Research. 1994; 23:95-96. Yang H, Han Y, Huang L.

  68. A study on cadmium content in foods of six provinces and cities. J. Chinese Preventive Medicine. 1994; 28:6-8. Yang H, Zou Z, Jin C, Gu W, Liang C, Yi F, Xie B, Huang, L.